Company Overview

Development Stage

About the Company

诺泰生物(股票代码:688076)是一家集研发、生产、销售为一体的综合型医药上市公司,成立于 2009年9月,主要业务涵盖多肽药物及小分子化学仿制药的原料药及制剂研发及生产,CDMO高级医药中间体定制合成研发及工业化生产等。 集团总部位于杭州市未来科技城(杭州师范大学科技园),是省级重点扶持高新技术企业,公司设立1个药物研究院,2个生产基地。 药物研究院位于杭州余杭区未来科技城,由6名海归博士领衔带队的150余人的研发团队,从事小分子化药、多肽药物及高端定制原料药、中间体的研发与注册申报工作。连云港工厂建成了符合 GMP要求的 3个 API车间和 2个制剂车间。其中多肽原料药车间已通过美国 FDA认证;已建立的多肽产品库,储备了 50多个多肽产品技术包括心脑血管系统、抗肿瘤、免疫调节和辅助生殖等,可提供从克级到公斤级订单的供货;建德工厂致力于新药注册中间体及新药原料药的研发与生产,已陆续开发了十余项抗癌药物、抗抑郁药、抗肝炎药物的注册中间体等高新技术产品研发生产的产品均为全球首创产品,且全部出口美国、欧洲、日本等工业发达的国家及地区。 并与美国礼来公司、默克制药、辉瑞公司等多家世界500强企业建立了长期的技术合作关系。 诺泰生物经过多年的发展,通过技术、产品、市场等的积累,厚积薄发,前期的技术成果正在向产业化实现转化,研发、新产品注册申报及销售等呈现可喜势头,公司正在步入快速发展的轨道。 诺守诚信,泰然兴业。诺泰生物一直秉承以建设国内一流、国际知名、具有核心竞争力的创新型高科技生物医药企业为目标,锐意进取、勇于创新,不断实现企业的新发展、新跨越。一、薪资福利:1.所有研发岗位结合项目经验,确定技术等级,一人一议,提供具有市场竞争力的薪资! 2.薪资结构:基本月薪+餐补20元/工作日+交通补贴125元/月+年终奖金+项目奖金; 3.各类补贴齐全:餐补、交通补贴、下工厂补贴、出差补贴、高温补贴等! 4.依据当年度公司经营效益,每年制定调薪方案; 5.缴纳五险一金、享受法定假日、带薪年休假、年度福利体检、入离职职业健康体检、丰富的节日礼品,如春节、中秋节、妇女节等; 5.贴心的人事服务,让您入职无后顾之忧:为符合杭州人才引进政策的同事办理各项人才补贴、租房补贴、生活补贴、公租房补贴、人才认定等!协助员工办理党员关系转移、五险一金转移、人才居住证、人才落户、杭州市职称评定等!

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

How Fast Is Hiring Growing? (14 open positions)

Manage
Note: How fast is hiring at 杭州诺泰澳赛诺医药技术开发有限公司 growing? 2026: 30 openings (down 47%), 2025: 57 openings (up 148%), 2024: 23 openings (down 79%), 2023: 107 openings (up 234%), 2022: 32 openings (down 30%), 2021: 46 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 10%
  • 2024: Down 41%
  • 2023: Up 467%
  • 2022: Flat 0%-
Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at 杭州诺泰澳赛诺医药技术开发有限公司 growing? Master's recruitment over the years: 2025: 11 openings (up 10%), 2024: 10 openings (down 41%), 2023: 17 openings (up 467%), 2022: 3 openings (flat), 2021: 3 openings.

Doctoral Degree Job Demand Analysis

(More)
+50%
Growth Rate
2026 vs 2025
  • 2025: Up 100%
  • 2024: Down 91%
  • 2023: Up 1000%
  • 2022: Down 50%
Doctoral Hiring by Year: 2026 — 1 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at 杭州诺泰澳赛诺医药技术开发有限公司 growing? Doctorate recruitment over the years: 2026: 3 openings (up 50%), 2025: 2 openings (up 100%), 2024: 1 openings (down 91%), 2023: 11 openings (up 1000%), 2022: 1 openings (down 50%), 2021: 2 openings.

R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at 杭州诺泰澳赛诺医药技术开发有限公司? Based on an analysis of 's job postings over the past year, "生物/制药/化工/环保类" demand: 61.5%, "其他(研发和技术类)": 41%, "科研类": 33.3%, "医疗卫生/美容保健类": 12.8%, "计算机/网络/技术类": 7.7%. For reference only.

— What Are the Salaries Like? (39 records)

Manage
salary range: 2K - 50K, 76.9% of roles pay ¥10-50K
Note: salary statistics are based on 39 salary records from the past year and depend on the job sample. For reference only.
How is the salary at 杭州诺泰澳赛诺医药技术开发有限公司?76.9% of positions earn 10-50K, Fresh graduate salary: ¥15.0K。Hangzhou salary ranking: #670,生物/制药/化工/环保类 average salary ¥25.1K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of

(More)
Are salaries high at 杭州诺泰澳赛诺医药技术开发有限公司? We provide: 研究员,bd,分析,dm,实习生,制剂总监,医药研发,药物合成,行政,运维,it主管,内控,制剂研发,制剂研究,司机,合成技术员,审计,投标,拓展,有机合成. Click to view detailed salary analysis by job.

honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Related Industry Tags

Job Category

  • 生物/制药/化工/环保类
    61.5% of total 61.5%
  • 其他(研发和技术类)
    41% of total 41%
  • 科研类
    33.3% of total 33.3%
  • 经营管理类
    28.2% of total 28.2%

Education

  • 本科
    56.4% of total 56.4%
  • 硕士
    28.2% of total 28.2%
  • 博士
    10.3% of total 10.3%
  • 高中
    2.6% of total 2.6%

Experience

  • 3-5年
    30.8% of total 30.8%
  • 不限
    23.1% of total 23.1%
  • 1-3年
    20.5% of total 20.5%
  • 5-10年
    20.5% of total 20.5%
View Detailed Analysis

What does 杭州诺泰澳赛诺医药技术开发有限公司 require? Who is 杭州诺泰澳赛诺医药技术开发有限公司 hiring? recruitment: 生物/制药/化工/环保类占比最多占61.5%,其次是其他(研发和技术类)占41%. What education can get in at ? 本科占比最多占56.4%,其次是硕士占28.2%. High education required at ? 硕士占28.2%,博士占10.3%. Work experience required at ? 3-5年占比最多占30.8%,其次是不限占23.1%. Where are the job locations at ? 杭州占比最多占94.9%,其次是连云港占5.1%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 4,200万(元)
Legal Representative: 赵德中
Date Established:
Credit Code: 91330183328163241H
Registered Address: 浙江省杭州市余杭区仓前街道文一西路1378号E座1201、1203室

Partners & Suppliers

诺泰生物与浙江大学有产学研合作,共同开展多肽药物相关研究 Source
供应商 高校/研究院合作
诺泰生物为豪森药业提供多肽原料药CDMO服务 Source
合作客户 多肽原料药客户
诺泰生物为九源基因提供多肽原料药CDMO服务 Source
合作客户 多肽原料药客户
诺泰生物为前沿生物提供多肽原料药(艾博韦泰)的CDMO服务 Source
合作客户 多肽原料药客户

People who follow this company also follow

Competitors (Similar Companies)

生物科技/生物工程 生物制剂 药物研发 生物医药
“Research, development, and production of anti-tumor and surgical medic”
制药/药业 医药 生物制药 医药中间体
“A provincial high-tech enterprise specializing in the development, pro”
“Peptides, chemical and biological APIs and preparations”
生物制药 医药 抗体 药物研发
水剂 单克隆抗体药物 纳米抗体 CDMO
“Mainly engaged in the production and sales of antibiotics, traditional”
制药/药业 医药 医药工业 医药中间体
“全球称重领域物联网研发与推广应用的主要企业之一”
“直接接触各类注射剂类药物包装的研发制造和销售”
肉制品 农产品 农产品加工 生猪养殖
制药/药业 原料药 中间体生产 医药
制药/药业 软膏剂 医药 原料药
“婴儿保育设备专业制造商”

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates